The key to Alexion Pharmaceuticals (ALXN) is Soliris. Morgan Stanley says the blockbuster blood disease drug could generate an extra $1 billion in sales if it gets approved to treat additional rare diseases next year. Two additional drugs are poised to launch in the coming months as well.

Related: Doomed cholesterol drug causes Eli Lilly's worst day since 2008